TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04821934

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TR
Description: TR is a specific remote tele rehabilitation program on exercise activity managed by the physiotherapist (PT) at home, this is the experimental group. PT will explain the rehabilitation program at hospital discharge by the use of a brochure and videos. TR will include an early exercise re-conditioning program \[aerobic exercise at the free body (with or without tools), cyclette and walking with a pedometer\] comprising 20 sessions of 60 minutes/day, 6 out of 7 days to be performed at home, for one month after discharge. The sessions will be self-managed by the patients 4 times a week and an expert PT will remotely supervise 2 times a week through a dedicated platform. The program will be progressively incremental and divided into 4 different levels of intensity (0- 3).~In addition to this specific rehabilitation program, the patients will be followed by a nurse tutor once a day for two weeks and once a week for a further two weeks in a program of Telesurveillance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TSu
Description: The patients of this group will perform a usual Telesurveillance and will be considered as control group.~All patients, at discharge from the hospital, will be provided with a finger pulse oximeter and a dedicated application (app) on their personal smartphone and will be advised on free physical activity to be performed at home. The nurse will check through scheduled calls (once a day for two weeks and once a week for a further two weeks) the patient's health condition, vital parameters and drugs administration. Patients will be able to contact the nurse at each time, in case of specific need, out of the scheduled call, 7/7 days.~A follow up by phone will be planned by nurse tutor at 2 months from the end of the study.
Study: NCT05895097

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left bundle branch pacemaker
Description: Left bundle branch pacing (LBBP) will be the pacing technique. In brief, after localizing the His bundle area the LBBP lead will be positioned approximately 1-1.5 cm distal to the His bundle position in the right ventricular septum. Before screwing the lead deep into the interventricular septum, the suitable position will be confirmed by fluoroscopic signs and adequate paced QSR morphology. Final lead position will be confirmed according to ECG parameters. Given that the pacing parameters with LBBP are typically low and stable, backup RV lead will not be mandatory.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional pacing
Description: Right ventricular pacing in patients with LVEF ≥ 40% and cardiac resynchronization therapy in patients with LVEF \< 40 %
Study: NCT05183074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR-linac
Description: 1.5-Tesla MR-linac based SBRT
Study: NCT05982912

Intervention type: DIAGNOSTIC_TEST
Intervention: breath sampling
Description: We collect a breath sample of exhaled air and analyse the VOC profile in this sample
Study: NCT06285552

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive parenting PAIF program
Description: Psychoeducational intervention in a group format driven by a practitioner with 6 to 12 sessions where caregivers learn parenting competences

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive parenting PAIF program
Description: Psychoeducational intervention in a group format driven by a practitioner with 6 to 12 sessions where caregivers learn parenting competences

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive parenting PAIF program
Description: Psychoeducational intervention in a group format driven by a practitioner with 6 to 12 sessions where caregivers learn parenting competences

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive parenting PAIF program
Description: Psychoeducational intervention in a group format driven by a practitioner with 6 to 12 sessions where caregivers learn parenting competences

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive parenting PAIF program
Description: Psychoeducational intervention in a group format driven by a practitioner with 6 to 12 sessions where caregivers learn parenting competences

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive parenting PAIF program
Description: Psychoeducational intervention in a group format driven by a practitioner with 6 to 12 sessions where caregivers learn parenting competences

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive parenting PAIF program
Description: Psychoeducational intervention in a group format driven by a practitioner with 6 to 12 sessions where caregivers learn parenting competences
Study: NCT04532346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine Sulfate is an anti-malarial and anti-rheumatic drug. hydroxychloroquine has been reported to improve the clinical status of chILD cases wtih genetic causes. The exact mechanism of action of hydroxychloroquine is unknown. In additon to having anti-inflammatory properties, hydroxychloroquine has been shown to affect intracellular processing of surfactant protein.
Study: NCT05223998

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full-thickness skin microcolumns implantation
Description: Surgical harvest and implantation of FTSM on an open wound requiring coverage.
Study: NCT05644717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg, 15mg
Description: Ertugliflozin 5/15mg once daily in addition to standard of care
Study: NCT05238519

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interview (MI)
Description: The MI intervention is adapted from the CHEERS study intervention (M Health Fairview) found to be effective in promoting lipid screening in patients at increased risk for FH.~Within one month of completion of the baseline survey, a study coordinator, who received training in motivational interview integrity, will conduct a 20-40-minute (depending on participant needs) telephone or virtual (zoom) interview with participants randomized to this arm. Participants will be assessed on their readiness to get their cholesterol checked and discuss with family members the risk of FH.
Study: NCT05309967

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GLUMA DESINSITIZER
Description: GLUTARALDEHYDE

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: DESTILLED WATER
Study: NCT05593315

Intervention type: OTHER
Group type: OTHER
Intervention: Mindfulness and Buteyko techniques
Description: Joint implementation of a general relaxation program and a respiratory rehabilitation program in patients with poorly controlled asthma.
Study: NCT05749367

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine + saline solution
Description: SIFIB with 30 ml of 0.5% ropivacaine and PENG Block plus LFCNB with 20 ml and 10 ml of saline solution, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline solution + Ropivacaine
Description: SIFIB with 30 ml of saline solution and PENG Block plus LFCNB with 20 ml and 10 ml of 0,5% ropivacaine, respectively.
Study: NCT06288204

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Propolis + Royal Jelly
Description: The participants will consume 4 capsules a day, providing daily royal jelly in an amount of 100 mg/day plus 500 mg/day of propolis, for 2 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Royal Jelly
Description: The participants will consume 4 capsules a day, providing daily royal jelly in an amount of 100 mg/day, for 2 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participant will consume 4 capsules a day of placebo, for 2 months.
Study: NCT05656287

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS texts + incentives + Wisepill device for medication monitoring
Description: For the first two months, 54 participants will receive i) daily SMS medication reminders, ii) monthly mobile money for transport to the clinic, and iii) monthly mobile money incentives if \>90% medication adherence. For the remaining four months, the participants will receive: i) weekly medication SMS reminders, ii) monthly mobile money for transport to the clinic, iv) monthly mobile money incentives if \>90% medication adherence.
Study: NCT03698448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OligoG Dry powder for inhalation
Description: 10 capsules Dry Powder for Inhalation, BID
Study: NCT06469190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN5501
Description: Patients will receive Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Multiple doses of anti-CD19 CAR NK cells (KN5501) will infused in each group using the 3 + 3 dose-escalation strategy.
Study: NCT05978674

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: rocking bed group
Description: Babies assigned to the intervention group first will be placed on a rocking bed after routine care such as feeding and diaper changes and when the newborn is stable. A rocking attempt will be applied to the baby placed in the rocking bed for 30 minutes. After 30 minutes, the baby will not be lifted from the bed and will lie in bed for 90 minutes. After a period of two hours in total, the babies will be cared for and fed. Then, babies will be quota and control group measurements will be made.
Study: NCT05409703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: reiki therapy
Description: reiki therapy for nurses
Study: NCT06536543

Intervention type: OTHER
Intervention: Acute Respiratory Distress Syndrom (ARDS) treated with Prone Position (PP) equipped with Electrical Impedance Tomography (EIT)
Description: Positive End-Expiratory Pressure (PEEP) will be titrated with PEEP-EIT method as it is already done in usual care. A classical low flow Pression Volume (PV) curve will be done in order to detect airway closure and measure compliance, the acquisition of EIT data during PV curve will be analysed secondary with a dedicated software. Reconstruction of EIT derived PV curve will determine the regional airway opening pressures and compliances of the 2 lungs. Two decremental PEEP-EIT titrations will be compared, one in supine and the other just after turning in prone.
Study: NCT06712706

Intervention type: PROCEDURE
Intervention: Feeding jejunostomy placement
Description: Placement of feeding jejunostomy at staging laparoscopy

Intervention type: PROCEDURE
Intervention: Feeding jejunostomy placement at esophagectomy
Description: Placement of feeding jejunostomy at esophagectomy
Study: NCT05874505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab 80 mg at Day 0 then 40 mg subcutaneous at week 1, 3, 5, 7, 9, 11, 13 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab 162 mg subcutaneous each week for 15 weeks
Study: NCT04750343

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBP510 adjuvanted with AS03 (RBD 10μg/dose) - Stage 1
Description: Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with AS03 (RBD 10μg/dose) on Days 0 and 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBP510 (RBD 10μg/dose) - Stage 1
Description: Participants will receive intramuscular (IM) injections of GBP510 (RBD 10μg/dose) on Days 0 and 28.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline (0.9% sodium chloride solution) - Stage 1
Description: Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBP510 adjuvanted with AS03 (RBD 25μg/dose) - Stage 1
Description: Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with AS03 (RBD 25μg/dose) on Days 0 and 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBP510 (RBD 25μg/dose) - Stage 1
Description: Participants will receive intramuscular (IM) injections of GBP510 (RBD 25μg/dose) on Days 0 and 28.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline (0.9% sodium chloride solution) - Stage 1
Description: Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBP510 adjuvanted with AS03 (RBD 10μg/dose) - Stage 2
Description: Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with AS03 (RBD 10μg/dose) on Days 0 and 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBP510 adjuvanted with AS03 (RBD 25μg/dose)- Stage 2
Description: Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with AS03 (RBD 25μg/dose) on Days 0 and 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBP510 (RBD 25μg/dose)- Stage 2
Description: Participants will receive intramuscular (IM) injections of GBP510 (RBD 25μg/dose) on Days 0 and 28.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline (0.9% sodium chloride solution)- Stage 2
Description: Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
Study: NCT04219449

Intervention type: DIAGNOSTIC_TEST
Intervention: PT
Description: measuring PT drawn on citrated blood sample

Intervention type: DIAGNOSTIC_TEST
Intervention: Protein C
Description: measuring protein C drawn on citrated blood sample

Intervention type: DIAGNOSTIC_TEST
Intervention: Platelet aggregation by ADP and arachidonic acid
Description: measuring platelet aggregation drawn on citrated blood sample
Study: NCT06512870

Intervention type: DIAGNOSTIC_TEST
Intervention: Near infrared spectroscopy (NIRS)
Description: A technique that relies on differential absorption of infrared light to provide relative estimation of tissue oxygenation, has been successfully used to monitor perfusion of various tissues, including muscle tissue of the lower extremity.
Study: NCT05591755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution
Description: Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketotifen fumarate ophthalmic solution 0.035% (n = 56)
Description: Ketotifen fumarate ophthalmic solution 0.035% (n = 56)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate ophthalmic solution 0.025% (n = 56)
Description: Brimonidine tartrate ophthalmic solution 0.025% (n = 56)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Vehicle ophthalmic solution (n = 56)
Description: Experimental: Vehicle ophthalmic solution (n = 56)
Study: NCT06220149

Intervention type: DIAGNOSTIC_TEST
Intervention: FIT (fecal immunochemical test)
Description: A FIT (fecal immunochemical test) will be done daily for the 14 days following polypectomy.
Study: NCT06257680

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ReT01 ACT
Description: Patients were infused with ReT01 ACT injection after pretreatment, and subjects were closely observed for 24 hours after each infusion.
Study: NCT05656287

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS texts only + Wisepill device for medication monitoring
Description: For the first 2 months, 54 participants will receive daily SMS medication reminders, ii). For the remaining 4 months, the participants will receive weekly medication SMS reminders. All participants will also receive a Wisepill device for medication monitoring.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wisepill device for medication monitoring only
Description: Participants (54) in the Control arm will not receive SMS reminders or mobile money. All participants will also receive a Wisepill device for medication monitoring.
Study: NCT04562532

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microport Firehawk stent
Description: MicroPort Firehawk biodegradable polymer rapamycin target eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent)
Description: * Everolimus eluting stents (Xience family - Abbott Vascular, Promus family- Boston Scientific, Synergy - Boston Scientific)~* Zotarolimus eluting stents (Resolute/Onyx family and Endeavor- Medtronic)~* Sirolimus eluting stents (Orsiro- Biotronik)
Study: NCT05586815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colistin
Description: 150 mg every 8 hours intravenously for at least 7 and up to a maximum of 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colistin
Description: 150 mg every 8 hours intravenously for at least 7 and up to a maximum of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 200 mg every 12 hours orally for at least 7 and up to a maximum of 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsule without active compound
Study: NCT03698448

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OligoG Dry powder for inhalation
Description: 10 capsules Dry Powder for Inhalation, BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OligoG Dry powder for inhalation
Description: 10 capsules Dry Powder for Inhalation, BID
Study: NCT05344248

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS005 (recombinant humanized monoclonal antibody against IL-17A)
Description: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: JS005 placebo
Description: Subcutaneous injection
Study: NCT06420999

Intervention type: OTHER
Intervention: Diaphragmatic ultrasound and data collection
Description: At the inclusion visit, anamnestic data available in the medical record and clinical data (vitals, chest X-ray) will be collected. At the same time, a diaphragmatic ultrasound will be performed in the half-seated position to measure diaphragmatic excursion and the thickening fraction of the right hemi-diaphragm at rest. A follow-up visit will be made on the day of discharge from intensive care, during which diaphragmatic ultrasound will be performed At D90 (+/- 15 days), the following information will be collected by consulting the electronic medical record, or by telephone if the information is not available in the record: date of discharge from hospital, date of death, date and reason for readmission to hospital or intensive care, possible introduction of long-term non-invasive ventilation, new respiratory complication after discharge from intensive care (pneumonia, atelectasis).
Study: NCT05687981

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: the use of higher concentration of bupivacaine in ilioinguinal and iliohypogastric nerve block (IINB) might increase the efficacy of postoperative analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 2 mg dexamethasone
Study: NCT05941663

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dental implant surface
Description: Implants provided were Bone Level Tapered (Bone Level Tapered) Roxolid® implants with a SLActive® or SLActive® surface

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dental implant surface
Description: Implants provided were Bone Level Tapered (Bone Level Tapered) Roxolid® implants with a SLActive® or SLActive® surface
Study: NCT04879784

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05157711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anusol
Description: Daily at night and in the morning and after each bowel movement for two weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Relief [Name]
Description: Daily at night and in the morning and after each bowel movement for two weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily at night and in the morning and after each bowel movement for two weeks
Study: NCT05813314

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: BMN 111 administration via Injector Pen
Description: BMN 111 Injection will be given using an injector pen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMN 111 administration via vial and syringe
Description: BMN 111 Injection will be given using vial and syringe
Study: NCT05738759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidural Anesthetic Cocktail
Description: The anesthetic cocktail, consists of triamcinolone 40 mg, marcaine 5 mg, and morphine 3 mg, is soaked in the gelfoam size 1x2 cm and applied on the epidura before removal of the endoscope.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is soaked with NSS in the gelfoam size 1x2 cm as well and applied on the epidura before removal of the endoscope.
Study: NCT05837572

Intervention type: OTHER
Group type: OTHER
Intervention: Standardized meal
Description: Assessment of the validity of the ES-LFPQ: Each participant will complete the ES-LFPQ in before (fasted state) and after a standardized meal (fed state).~Evaluation of the reproducibility of the ES-LFPQ: With at least one week of difference between tests, each participant will repeat the same protocol performed in the previous visit and under the same conditions.
Study: NCT06150508

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: O2O digital healthcare service
Description: The O2O service includes a mobile app and web-based portal that allows patients to monitor their blood glucose levels, track their medication use and physical activity, receive personalized feedback and education, and communicate with healthcare providers. The treatment group will receive a blood sugar checker and blood pressure checker that send the records automatically to the application through Bluetooth.
Study: NCT04974866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR-TK Inhibitor
Description: epidermal growth factor receptor tyrosine kinase inhibitors
Study: NCT05748613

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Anxiety Sensitivity Treatment
Description: Brief computerized treatment for anxiety sensitivity

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health Education Control
Description: Brief computerized presentation on healthy behaviors
Study: NCT06289153

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arthrex Internal Brace
Description: The Arthrex Internal Brace method for ACL reconstruction consists of suture tape used to reinforce the ACL during surgery. This suture tape is secured in place with bioabsorbable anchors that gradually degrade within the body over time.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL Reconstruction
Description: All patients will undergo ACL reconstruction (ACLR) with or without an internal brace.